Brief: ABVC Biopharma ADHD Phase II Part 2 Clinical Study First Subject Treated
10/05/2022 14:04
May 10 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA ADHD PHASE II PART 2 CLINICAL STUDY FIRST
SUBJECT
TREATED
Source text for Eikon: ID:nGNXz5PP7
Further company coverage: ABVC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner